Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.

Assessing the Clinical Impact of Arthrosamid on Medial-Compartment Knee Osteoarthritis: Mechanisms, Efficacy, Safety and Future Directions
Arthrosamid® is a novel polyacrylamide hydrogel injection offering targeted, long-lasting relief for medial-compartment knee osteoarthritis, affecting millions worldwide. Unlike traditional treatments, Arthrosamid® delivers mechanical cushioning and improved joint lubrication through a single outpatient procedure, reducing pain and enhancing mobility. Clinical studies report significant symptom improvement lasting up to two years with minimal side effects, bridging the gap between medication and surgery. Ideal for patients unresponsive to conservative therapies, Arthrosamid® supports knee stability and quality of life. Ongoing research aims to validate long-term benefits and explore synergy with regenerative treatments, making Arthrosamid® a promising advancement in osteoarthritis care.